Gene Test Predicted Lung Cancer Therapy Benefit
A new diagnostic tool helped identify high-risk lung cancer patients who saw better outcomes with adjuvant chemotherapy.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Would you trust a gene test to decide whether to undergo post-surgery chemotherapy?
A gene-based assay called RiskReveal successfully identified early-stage non-small cell lung cancer patients who had improved survival rates when treated with adjuvant chemotherapy. Presented in September 2026, these findings may eventually influence clinical guidelines for post-surgical lung cancer care.
Why it matters
Current methods for predicting which early-stage lung cancer patients will benefit from chemotherapy after surgery have historically underperformed in clinical trials. This development offers a potential way to better tailor treatment to the patients most likely to see meaningful survival improvements.
In the AIM-HIGH trial of 236 high-risk patients, those receiving adjuvant platinum-based chemotherapy achieved a 96% two-year disease-free survival rate compared to 79% for those in the observation group. Additionally, a 101-person cohort followed since 2012 reported five-year overall survival at 97% for treated patients versus 80% for the observation group.
The players
RiskReveal
A gene expression assay that identifies recurrence risk in non-small cell lung cancer patients to inform chemotherapy decisions.
The details
The RiskReveal assay works by using polymerase chain reaction technology to analyze the expression of 14 specific genes—11 linked to cancer and three reference genes—within surgically resected tumor tissue. By categorizing the tumors as high, intermediate, or low risk for recurrence, the tool allows clinicians to identify which patients may achieve a survival benefit from four cycles of platinum-based chemotherapy. The process seeks to refine the selection of candidates for aggressive adjuvant therapy after standard surgical resection.
Timeline
Researchers began monitoring the 101-person secondary survival cohort in 2012.
The results were presented in September 2026 at the World Congress on Lung Cancer.
Health Landscape
This research follows a pattern of breakthroughs presented at the World Congress on Lung Cancer that seek to move beyond traditional staging when choosing adjuvant therapies. It sits within a growing effort to improve precision oncology for non-small cell lung cancer by identifying specific tumor markers.
If you or a family member are undergoing surgery for early-stage lung cancer, it is worth discussing with your doctor whether genetic testing for recurrence risk is available. Your medical team can determine if such diagnostics are appropriate for your specific tumor profile and current treatment path.
The takeaway
This assay represents a step toward more accurate, biology-based treatment decisions for those facing early-stage lung cancer. Ask your oncology team about the role of genomic testing in your post-surgical care plan.
Further reading
For more on evolving research in this field, visit the Cancer section.
Live Poll
Would you trust a gene test to decide whether to undergo post-surgery chemotherapy?
